Evidence map›Paper›PMID 39415149›Full record

ArticleBMC cancer2024

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.

Philipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller and 21 more

2 registry-linked trialsAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02338167 recruitingnot on this map

Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Adjuvant and Advanced/Metastatic Setting: Health Care Research, Pharmacogenomics, Biomarkers, Health Economics

Typeobservational_patient_registrySponsorUniversity Hospital TuebingenRan2014 to 2030Enrolled13,500ConditionsAdvanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)ArmsBlood sampling
NCT07238894 narecruitingnot on this mapstarted 2026, after this paper: background citation

Peking University People's Hospital Breast Surgery Department

TypeinterventionalSponsorPeking University People's HospitalRan2026 to 2028Enrolled200ConditionsAblation, Breast CancerArmsCombined Cryoablation and Thermal Ablation system
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Exercise therapy in cancer prevention and treatment.Nature reviews. Clinical oncology · 2026
    Review
  2. The effects of nutritional habits and physical activity on treatment response and survival in patients with lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Philipp ZieglerDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.
Andreas D HartkopfDepartment of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Markus WallwienerDepartment of Gynecology, Halle University Hospital, Halle, Germany.
Lothar HäberleDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.
Hans-Christian KolbergDepartment of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
Peyman HadjiFrankfurt Center for Bone Health, Frankfurt Am Main, Germany.
Hans TeschOncology Practice, Bethanien Hospital, Frankfurt Am Main, Germany.
Johannes EttlDepartment of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
Diana LüftnerImmanuel Hospital Märkische Schweiz & Immanuel Campus Rüdersdorf, Medical University of Brandenburg Theodor-Fontane, Rüdersdorf Bei Berlin, Germany.
Volkmar MüllerDepartment of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Laura L MichelNational Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg University Hospital, Heidelberg, Germany.
Erik BellevilleClinSol GmbH & Co KG, Würzburg, Germany.
Pauline WimbergerNational Center for Tumor Diseases Dresden and Department of Gynecology and Obstetrics, University Hospital Dresden, TU Dresden, Dresden, Germany.
Carsten Hielscherg.SUND Gynäkologie-Onkologisches Zentrum, Stralsund, Germany.
Hanna HuebnerDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.
Sabrina UhrigDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.
Lena A WurmthalerDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.
Carolin C HackDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.
Christoph MundhenkeDepartment of Gynecology and Obstetrics, Klinik Hohe Warte, Bayreuth, Germany.
Christian KurbacherDepartment of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany. peter.fasching@uk-erlangen.de.
Rachel WuerstleinDepartment of Gynecology and Obstetrics, Breast Center and CCC Munich, University Hospital LMU Munich, Munich, Germany.
Michael UntchDepartment of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Florin-Andrei TaranDepartment of Obstetrics and Gynecology, University Medical Center Freiburg, Freiburg, Germany.
Michael P LuxDepartment of Gynecology and Obstetrics, Frauenklinik St. LouiseSt. Josefs-KrankenhausVincenz Kliniken Salzkotten + Paderborn, Paderborn, Germany.
Diethelm WallwienerDepartment of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Sara Y BruckerDepartment of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Tanja N FehmDepartment of Gynecology and Obstetrics, Düsseldorf University Hospital, Düsseldorf, Germany.
Andreas SchneeweissNational Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg University Hospital, Heidelberg, Germany.
Chloë GoossensDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the different molecular cancer subtypes. Therefore, we here evaluated the effect of physical activity on progression-free and overall survival (PFS, OS) in metastatic breast cancer, specifically looking at molecular subtypes.

methodsInternational Physical Activity Questionnaire (IPAQ) questionnaires, filled out by patients enrolled in the prospective PRAEGNANT registry (NCT02338167; n = 1,270) were used to calculate metabolic equivalent task (MET) minutes, which were subsequently categorized into low (n = 138), moderate (n = 995) or high IPAQ categories (n = 137). Cox regression analyses were used to evaluate the impact of IPAQ categories and its interaction with molecular subtypes on PFS and OS.

resultsPatient and tumor characteristics were equally distributed across IPAQ categories. HER2pos, HRpos and TNBC were present in 23.1%, 65.7% and 11.2% of patients, respectively. IPAQ scores did not have an impact on PFS and OS in addition to established prognostic factors, either overall or in particular molecular subtypes (PFS: p = 0.33 and OS: p = 0.08, likelihood ratio test). Exploratory analyses showed higher overall survival rates for high IPAQ categories compared to low/moderate IPAQ categories in luminal B-like breast cancer.

conclusionsSelf-reported physical activity using the IPAQ questionnaire did not significantly affect PFS or OS in patients suffering from metastatic breast cancer. Nevertheless, some hypothesis-generating differences between molecular subtypes could be observed, which may be interesting to evaluate further.

Indexed as

Breast NeoplasmsExerciseAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisProgression-Free SurvivalProspective StudiesRegistriesSurveys and QuestionnairesErb-b2 Receptor Tyrosine KinasesIPAQMetastatic breast cancerMolecular subtypePhysical activity

Identifiers

PMID39415149
PMCPMC11481816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.